To the full analysis
Buyback calculator for Assembly Biosciences
Assembly Biosciences stock: key metrics
ASMBAssembly Biosciences had an operating margin of −16.8% and a return on invested capital (ROIC) of −6.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | −390.4% | −579.1% | −474.7% |
| 2018 | −391.4% | −626.4% | −613.0% |
| 2019 | −434.5% | −643.4% | −611.6% |
| 2020 | −28.1% | −81.9% | −78.6% |
| 2021 | 100.0% | −2,121.7% | −2,076.4% |
| 2022 | no data | no data | no data |
| 2023 | −582.7% | −902.5% | −854.8% |
| 2024 | −96.1% | −159.3% | −140.9% |
| 2025 | 99.8% | −16.8% | −8.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | 92.9% | no data | −100.0% |
| 2009 | 34.0% | no data | −100.0% |
| 2010 | −100.0% | −77.1% | −100.0% |
| 2011 | −99.5% | no data | −92.7% |
| 2012 | −100.0% | −75.0% | −100.0% |
| 2013 | −79.2% | −73.2% | −71.5% |
| 2014 | −40.6% | −40.0% | −33.4% |
| 2015 | −24.0% | −58.2% | −21.3% |
| 2016 | −55.4% | −91.7% | −45.1% |
| 2017 | −37.8% | −33.4% | −25.3% |
| 2018 | −43.1% | −36.1% | −33.9% |
| 2019 | −35.7% | −28.2% | −28.1% |
| 2020 | −25.8% | −17.5% | −21.9% |
| 2021 | −76.9% | −48.3% | −68.0% |
| 2022 | −100.0% | −57.1% | −91.5% |
| 2023 | −100.0% | −55.8% | −44.7% |
| 2024 | −100.0% | −42.5% | −33.7% |
| 2025 | −3.0% | −6.8% | −2.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2011)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.